A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients

Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity

Advances in PSMA-directed Radionuclide Therapy

Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer

State-of-the-industry video lectures by leading urology experts
Featured Videos

#ASCO14 - Poster: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel

CHICAGO, IL USA ( - Presented by Karim Fizazi, Robert Jones, Stephane Oudard, Eleni Efstathiou, Fred Saad, Ronald De Wit, Johann Sebastian De Bono, Felipe Cruz, George Fountzilas, Albertas Ulys, Flavio Carcano, Neeraj Agarwal, David B. Agus, Joaquim Bellmunt, Daniel Peter Petrylak, Connie Lee, Bindu Tejura, Niels Geert Borgstein, and Robert Dreicer at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

 asco 2014 fizazi poster 5042 thumb

Institut Gustave Roussy, University of Paris Sud, Villejuif, France; University of Glasgow, Institute of Cancer Sciences, Glasgow, United Kingdom; HEGP, Paris, Université Paris Descartes, Paris, France; Alexandra General Hospital of Athens, Oncology Department, Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece; University of Montréal Hospital Center, Montréal, QC, Canada; Erasmus University Medical Center, Rotterdam, Netherlands; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; ABC Foundation School of Medicine, Santo André, Brazil; Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Hospital de Cancer de Barretos, Barretos-SP, Brazil; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of Southern California, Los Angeles, CA; Dana-Farber Cancer Center Institute/Brigham and Women's Cancer Center, Boston, MA; Columbia University Medical Center, New York, NY; Takeda Pharmaceuticals International Co., Cambridge, MA; Cleveland Clinic, Cleveland, OH 



Conference Coverage
Recent data from conferences worldwide
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Publications focusing on urologic cancer treatments through original manuscripts